Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1988 2
1989 9
1990 20
1991 30
1992 32
1993 34
1994 42
1995 54
1996 62
1997 42
1998 50
1999 46
2000 42
2001 51
2002 49
2003 61
2004 55
2005 79
2006 79
2007 86
2008 83
2009 86
2010 81
2011 80
2012 82
2013 81
2014 83
2015 77
2016 85
2017 49
2018 56
2019 59
2020 64
2021 74
2022 63
2023 33

Text availability

Article attribute

Article type

Publication date

Search Results

1,896 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV; ASCEND-D Study Group. Singh AK, et al. N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5. N Engl J Med. 2021. PMID: 34739194 Clinical Trial.
BACKGROUND: Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adverse events. ...METHODS: In …
BACKGROUND: Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the …
Erythropoietin: biology and clinical use.
Graber SE, Krantz SB. Graber SE, et al. Hematol Oncol Clin North Am. 1989 Sep;3(3):369-400. Hematol Oncol Clin North Am. 1989. PMID: 2561121 Review.
Red cell production in vertebrates is controlled by a glycoprotein hormone known as erythropoietin (Ep), which is produced by the kidney in response to hypoxia and acts on the marrow to selectively stimulate erythropoiesis. ...However, since Ep exists in plasma in several …
Red cell production in vertebrates is controlled by a glycoprotein hormone known as erythropoietin (Ep), which is produced by the kid …
Erythropoietin or darbepoetin for patients with cancer.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Tonia T, et al. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5. Cochrane Database Syst Rev. 2012. PMID: 23235597 Free PMC article. Review.
The increased risk of death and thromboembolic events should be balanced against the potential benefits of ESA treatment taking into account each patient's clinical circumstances and preferences. More data are needed for the effect of these drugs on quality of life and tum …
The increased risk of death and thromboembolic events should be balanced against the potential benefits of ESA treatment taking into account …
Erythropoietin or darbepoetin for patients with cancer.
Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Bohlius J, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003407. doi: 10.1002/14651858.CD003407.pub4. Cochrane Database Syst Rev. 2006. PMID: 16856007 Updated. Review.
BACKGROUND: Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant human erythropoietin (Epo), darbepoetin (Darbepo) and red blood cell transfusions. ...
BACKGROUND: Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therap …
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE. Fishbane S, et al. J Am Soc Nephrol. 2022 Apr;33(4):850-866. doi: 10.1681/ASN.2020111638. J Am Soc Nephrol. 2022. PMID: 35361724 Free PMC article. Clinical Trial.
Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoietin and iron availability. METHODS: In this open-label phase 3 study, patients with DD-CKD and anemia were randomized 1:1 to oral roxadu …
Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoie …
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Chen N, et al. N Engl J Med. 2019 Sep 12;381(11):1011-1022. doi: 10.1056/NEJMoa1901713. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31340116 Clinical Trial.
METHODS: In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-stimulating agent therapy with epoetin alfa for at least 6 weeks to receive roxadustat or epoetin alfa three time …
METHODS: In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-s …
Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer.
Lambin P, Ramaekers BL, van Mastrigt GA, Van den Ende P, de Jong J, De Ruysscher DK, Pijls-Johannesma M. Lambin P, et al. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006158. doi: 10.1002/14651858.CD006158.pub2. Cochrane Database Syst Rev. 2009. PMID: 19588382 Review.
It has therefore been hypothesised that correcting anaemia, by increasing haemoglobin levels using erythropoietin, improves tumour oxygenation and consequently the patient's prognosis. OBJECTIVES: To assess whether combined treatment with radiotherapy and erythro …
It has therefore been hypothesised that correcting anaemia, by increasing haemoglobin levels using erythropoietin, improves tumour ox …
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Bohlius J, et al. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD007303. doi: 10.1002/14651858.CD007303.pub2. Cochrane Database Syst Rev. 2009. PMID: 19588423 Free PMC article. Review.
SELECTION CRITERIA: We included randomized controlled trials comparing epoetin or darbepoetin plus red blood cell transfusions (as necessary) versus red blood cell transfusions (as necessary) alone, to prevent or treat anemia in adult or pediatric cancer patients with or w …
SELECTION CRITERIA: We included randomized controlled trials comparing epoetin or darbepoetin plus red blood cell transfusions (as ne …
Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.
Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Bohlius J, et al. J Natl Cancer Inst. 2005 Apr 6;97(7):489-98. doi: 10.1093/jnci/dji087. J Natl Cancer Inst. 2005. PMID: 15812074 Review.
We included all randomized controlled trials that compared the use of recombinant human erythropoietin (plus transfusion, if needed) with no erythropoietin treatment (plus transfusion, if needed). ...CONCLUSIONS: Erythropoietin treatment may reduce the risk f …
We included all randomized controlled trials that compared the use of recombinant human erythropoietin (plus transfusion, if needed) …
Recombinant human erythropoietin use in intensive care.
Darveau M, Notebaert E, Denault AY, Bélisle S. Darveau M, et al. Ann Pharmacother. 2002 Jun;36(6):1068-74. doi: 10.1345/aph.1A323. Ann Pharmacother. 2002. PMID: 12022910 Review.
OBJECTIVE: To review the literature concerning the role of recombinant human erythropoietin (rHuEPO) in reducing the need for transfusion in critically ill patients. DATA SOURCES: Articles were obtained through searches of the MEDLINE database (from 1990 to June 2001) usin …
OBJECTIVE: To review the literature concerning the role of recombinant human erythropoietin (rHuEPO) in reducing the need for transfu …
1,896 results

Searches related to "erythropoietin"